InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,695.94
(
-0.96%
)
US TECH 100
19,375.60
(
0.48%
)
Dow Jones
41,954.24
(
0.00%
)
Brent Oil
79.14
(
-2.22%
)
Bitcoin
62,539.78
(
0.51%
)
Post# of 253292
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

NP1986

Send PM Follow Ignore
Followers 6
Posts 541
Boards Moderated 0
Alias Born 06/07/2011

NP1986

Re: pcrutch post# 127820

Wednesday, 10/05/2011 12:36:42 PM

Wednesday, October 05, 2011 12:36:42 PM

Post# of 253292
It will be interesting to see if Votrient gets a priority review from the FDA. Granted it is for second line therapy of sarcomas where there does seem to be an unmet need.

I don't think maintenance therapy really qualifies as an "unmet need" which could be why the FDA did not grant priority review for ridaforolimus.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up